CD19-targeted CAR-T cells have made breakthrough progress in the treatment of B-cell malignancies, with multiple clinical studies showing that CD19 CAR-T cells can induce complete remission in up to 80–90% of patients with refractory or relapsed B-cell leukemia and lymphoma (49). This evidence concerns the gene CD19 and lymphoma.